The BCL2L11 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the BCL2L11 gene has been functionally disrupted. This product provides a genetically defined loss-of-function model for studying the role of BIM, the protein encoded by BCL2L11, in intrinsic apoptosis and cancer cell survival. The polyclonal nature of the edited pool reflects the heterogeneous editing outcomes typical of CRISPR/Cas9-mediated gene disruption, avoiding clonal artifacts while maintaining a uniformly null phenotype across the population.
The host HAP1 cell line is a human near-haploid chronic myeloid leukemia derivative of the KBM-7 line, possessing a modal chromosome number of 25. This haploid karyotype renders HAP1 cells exceptionally suited for genetic knockout and screening applications, as a single disruptive edit per gene can unmask complete loss-of-function phenotypes without confounding effects from a second allele. The CML origin of HAP1 cells also endows them with active BCR-ABL signaling, a hallmark driver of leukemogenesis that suppresses pro-apoptotic pathways.
BCL2L11 encodes BIM, a BH3-only member of the BCL-2 family that functions as a principal sensor and initiator of the intrinsic apoptotic cascade. BIM is transcriptionally regulated by FOXO3a and E2F1, and is post-translationally controlled by phosphorylation: JNK-mediated phosphorylation activates BIM, while ERK-directed phosphorylation marks it for proteasomal degradation. In response to apoptotic stimuli, BIM neutralizes anti-apoptotic proteins such as BCL-2, BCL-XL, and MCL-1, thereby releasing BAX and BAK to homo-oligomerize at the mitochondrial outer membrane. This event triggers mitochondrial outer membrane permeabilization, cytochrome c release, APAF1 apoptosome formation, and subsequent activation of caspase-9 and caspase-3. Additionally, BIM interacts with dynein light chain LC8, linking its function to cytoskeletal dynamics.
In the HAP1 cellular context, BIM acts as a critical pro-apoptotic barrier against BCR-ABL-driven survival signaling. BCR-ABL suppresses BIM expression through multiple mechanisms, contributing to the apoptotic resistance of CML cells. Therefore, deletion of BCL2L11 in this background creates a clean model to dissect BCR-ABL-mediated survival, to explore synthetic lethal vulnerabilities, and to screen for compounds that can restore apoptosis independently of BIM.
Researchers can apply this polyclonal knockout model in a variety of experimental settings, including intrinsic apoptosis pathway analysis, functional screening of BH3 mimetics, and drug sensitivity profiling with agents such as imatinib. Representative assays compatible with these cells include Western blotting for BIM, RT-qPCR for BCL2L11 mRNA, Annexin V binding assays, caspase-3/7 activity measurements, cytochrome c release detection, and mitochondrial membrane potential assessments using JC-1. The BIM-null background also enables genome-wide CRISPR screens to identify synthetic lethal targets that are selectively essential when BIM is lost. For additional details or custom project inquiries, please contact Ascent Research.
